Ace Therapeutics Unveils Advanced Genetic Kidney Disease Models to Accelerate Renal Drug Discovery

Key Abstract

Ace Therapeutics Launches Advanced Genetic Kidney Disease Models: Integrated platform designed to accelerate drug discovery for hereditary renal disorders.
High-Fidelity Translational Tools: Models accurately recapitulate human pathology, covering diseases like Alport Syndrome, Fabry Disease, and PKD.
Custom Model Generation: Utilizes CRISPR/Cas9 for novel targets, expanding research capabilities beyond standard offerings.
Comprehensive Preclinical Services: Includes efficacy testing, biomarker development, advanced imaging, and specialized gene therapy evaluation.

Impact - Why it Matters

Ace Therapeutics' new genetic kidney disease models are crucial for accelerating drug discovery in a field with limited treatments. By offering high-fidelity preclinical tools and comprehensive services, this launch empowers researchers to develop transformative therapies, ultimately improving outcomes for patients suffering from hereditary renal disorders and advancing the nephrology pipeline.

Summary

NEW YORK, NY, March 28, 2026 -- Ace Therapeutics has announced the launch of an integrated platform featuring comprehensive preclinical genetic kidney disease models. This cutting-edge platform is meticulously designed to accurately recapitulate human hereditary renal pathology, providing robust support for translational research aimed at drug developers globally. Genetic kidney diseases, stemming from inherited pathogenic mutations, represent a significant unmet medical need, characterized by progressive renal impairment and severely limited treatment options.

To address this critical challenge, Ace Therapeutics has developed and rigorously validated a suite of genetically engineered animal models. These models faithfully capture the core molecular, histological, and functional features of inherited renal disorders, enabling precise target validation, in-depth mechanistic investigation, and reliable therapeutic efficacy assessment. The platform covers a broad spectrum of hereditary nephropathies, including Alport Syndrome, FSGS, Fabry Disease, Polycystic Kidney Disease (PKD), and C3 Glomerulopathy, utilizing well-characterized knockout and conditional knockout rodent strains. Beyond standard offerings, Ace Therapeutics also provides custom model generation via CRISPR/Cas9 technology for novel targets, adhering to strict institutional animal care guidelines.

Complementing these advanced models, Ace Therapeutics offers end-to-end preclinical service capabilities, encompassing therapeutic efficacy testing, mechanistic profiling, biomarker development, and advanced imaging analytics. These services facilitate dose-response evaluations for small molecules, ASOs, and gene therapies, alongside specialized analyses like single-cell RNA sequencing and MRI-based cyst volumetry. Notably, the company enables specialized gene therapy testing in Fabry disease models, leveraging Gla knockout mice to assess AAV vector tropism, biodistribution, and therapeutic efficacy. This comprehensive offering solidifies Ace Therapeutics' position as a trusted partner for biotech and pharmaceutical companies advancing novel therapies for genetic kidney diseases.

Ace Therapeutics Unveils Advanced Genetic Kidney Disease Models to Accelerate Renal Drug Discovery

Key Abstract

Ace Therapeutics Launches Advanced Genetic Kidney Disease Models: Integrated platform designed to accelerate drug discovery for hereditary renal disorders.
High-Fidelity Translational Tools: Models accurately recapitulate human pathology, covering diseases like Alport Syndrome, Fabry Disease, and PKD.
Custom Model Generation: Utilizes CRISPR/Cas9 for novel targets, expanding research capabilities beyond standard offerings.
Comprehensive Preclinical Services: Includes efficacy testing, biomarker development, advanced imaging, and specialized gene therapy evaluation.